Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Antiviral Drugs Market size was USD 63.1 billion in 2024 and is estimated to reach USD 125.6 billion by the end of 2037, expanding at a CAGR of 7.3% during the forecast period, i.e., 2025-2037. In 2025, the industry size of antiviral drugs is estimated at USD 66.5 billion.
The antiviral drugs market caters to a significant patient pool, with influenza, hepatitis, and HIV representing the largest demand. As per the 2024 UNAIDS report, an estimated 40 million people reside with HIV internationally, further requiring long-term antiviral therapy. Besides, as stated in the 2023 WHO report, approximately 330 million chronic hepatitis B and C cases have been recorded, which is readily driving the need for direct-acting antivirals (DAAs). Besides, almost 1.5 billion people suffer from seasonal influenza, with high-risk populations depending on neuraminidase inhibitors. However, the administrative stockpile initiatives, including the EU’s HERA program and the U.S. Strategic National Stockpile (SNS), have amplified procurement volumes, thus suitable for market growth.
Moreover, the supply chain aspect in the antiviral drugs market effectively relies on the production of active pharmaceutical ingredients (APIs), with India and China dominating the worldwide supply by grabbing almost 70.5% market share. Meanwhile, the manufacturing process of finished-dose has been centralized in Europe and North America, and India is leading in the export of antiviral products, accounting for USD 25 billion as of 2024. Besides, trade dynamics demonstrated that China is the largest API exporter, constituting a valuation of USD 19 billion as of 2023, while the U.S. is the top importer of finished antivirals, catering to USD 33 billion as of 2024, thus boosting the market expansion.
